Key result
The modified assist device (MAD-5) achieved a maximum flow rate of 1.9 L/min in a mock circulatory system and provided effective systolic unloading and diastolic augmentation in an animal model.
Why the study?
Does the MAD-5 provide effective circulatory support in vitro and in vivo?
Does the MAD-5 provide effective circulatory support in vitro and in vivo?
The MAD-5 is a novel percutaneously accessible pulsatile left ventricular assist device that demonstrates effective hemodynamic support in preclinical models.
To provide percutaneous access, a new circulatory assist system was developed. We call this newly developed system the modified assist device (MAD). The system is composed of a sac-type blood pump and cannula. Inflow and outflow valves are mounted in the apex and at the side wall 10 cm from the apex of the cannula, respectively. During systole, the blood is sucked from the left ventricle through the inflow valve of the cannula connected to the blood pump, and during diastole, the blood is ejected to the root of the aorta through the outflow valve. In vitro and in vivo evaluations of the pump performance were performed. The maximum flow rate of 1.9 L/min was obtained in the mock circulatory system. In our animal experiment, effective systolic unloading and diastolic augmentation were observed by activation of this system during regular sinus rhythm. In conclusion, the MAD-5 is thought to be percutaneously accessible and increases systemic and coronary flow.
No takes yet. Share an insight, caveat, or question.
Imanishi et al. (1996) studied this question. Modified assist device (MAD-5) was evaluated on Pump performance (maximum flow rate, systolic unloading, diastolic augmentation). The modified assist device (MAD-5) achieved a maximum flow rate of 1.9 L/min in a mock circulatory system and provided effective systolic unloading and diastolic augmentation in an animal model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: